Skip to main content

Ionis Pharmaceuticals(IONS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low38.87
Day High39.72
Open:38.99
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
GlobeNewswire
New Higher Dose Nusinersen Efficacy and Safety Data Presented at World Muscle Society Congress, Highlight Potential to Maximize Benefit of Nusinersen in SMA
GlobeNewswire
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA
GlobeNewswire
Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis
GlobeNewswire
New Biomarker Data Add Further Evidence Supporting the Potential Benefit of SPINRAZAยฎ (nusinersen) in Infants and Toddlers with Unmet Clinical Needs after Gene Therapy
GlobeNewswire
New Data at Cure SMA Highlight Potential Benefit of SPINRAZAยฎ (nusinersen) in Infants and Toddlers with Unmet Clinical Needs After Gene Therapy

Profile

Ionis Pharmaceuticals discovers/develops RNA-targeted therapeutics using its proprietary antisense oligonucleotide technology. Its antisense medicines have been developed/are being developed to treat neurological, cardiovascular and specialty rare diseases.